氨曲南治疗铜绿假单胞菌肺炎42例

The Clinical Utility of Atreonam in 42 Patients with Pseudomonas Aeruginosa Pneumonia

目的评价氨曲南治疗铜绿假单胞菌肺炎的有效性和安全性。方法入选病例76例,可评价病例72例,随机分为试验组和对照组,试验组42例,给予氨曲南1～2g、iv、q12h,疗程14～21d;对照组30例,给予头孢他啶1～2g、iv、q12h,疗程14～21d。结果试验组、对照组有效率分别为90.5%(38/42)和83.3%(25/30);细菌清除率88.1%和66.7%,不良反应发生率分别为9.1%(4/44)和9.4%(3/32)。2组间均无显著性差异(P>0.05)。结论氨曲南治疗铜绿假单胞菌肺炎有效、安全,优于头孢他啶,值得推广应用。

Objective The present study sought to evaluate the clinical utility of atreonam in patients with pseudomonas aeruginosa pneumonia.Methods A total of 72 patients were finally enrolled in this study,and were randomly assigned to receive either atreonam （observation group,atreonam 1～2 g、iv、q12 h,14～21 d,42 patients） or Ceftazidime （contol group,Ceftazidime 1～2 g、iv、q12 h,14～21 d,20 patients） Results The total cure and efficiency rate were 76.2% （32/42） and 90.5% in the observation group,and were56.7% （17/30） and 83.3% in the control group.The rate of bacteriological elimination was 88.1% compared with data 66.7% in the control group.In observation and control group,the adverse reaction rate was 9.1% （4/44） and 9.4% （3/32）,respectively,and the significant differences were not found between two groups.Conclusion The drug therapeutic choice of atreonam in patients with pseudomonas aeruginosa pneumonia is safety and efficacy.